Suono Bio has developed breakthrough technology designed to enable ultra-rapid delivery of novel therapeutics, including proteins and nucleic acids, to the gastrointestinal (GI) tract. This technology has the potential to eliminate the need for formulation or encapsulation of the therapeutic and is amenable to use in multiple settings, including at home as well as in the clinic. The ability to deliver a broad range of novel therapies shows great promise in enhancing outcomes in a variety of GI-based diseases.
- Robert Langer, ScD Co-Founder
- Amy Schulman Co-Founder
- Giovanni Traverso, MD, PhD Co-Founder
- Carl Schoellhammer, PhD Co-Founder